International Stem Cell Corp to Participate in Upcoming Investor Conference

CARLSBAD, CA--(Marketwire - Sep 27, 2012) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and research products, today announced that Executive Vice President, Dr. Simon Craw will attend and present at the SeeThru Equity Fall Smallcap and Microcap Conference on October 2, 2012 at the Cornell Club in midtown Manhattan, NY.

SeeThru Equity Fall Smallcap and Microcap Conference Date: Tuesday, October 2, 2012 Time: 8:30 am EDT Location: The Cornell Club in midtown Manhattan, NY

Please contact the conference organizers if you have an interest in attending the conference or if you would like to arrange a meeting with International Stem Cell's management team. You may also contact Mark McPartland with MZ Group via email markmcp@mzgroup.us or phone 1-212-301-7130 to arrange a meeting with management.

You may register for the conference by clicking SeeThruEquity Fall Conference Attendee Registration or visting the SeeThru Equity website http://www.seethruequity.com

Additional information of the investor presentation will be available on the investor relations section of the Company's website http://www.internationalstemcell.com. A video replay webcast will be available for viewing approximately 24hours after the company presentation.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

Safe harbor statement

Continued here:
International Stem Cell Corp to Participate in Upcoming Investor Conference